Buy Furadonin pills 100 mg, 20 pcs
  • Buy Furadonin pills 100 mg, 20 pcs

Furadonin® [Nitrofurantoin]

593 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Furadonin - an antimicrobial drug, is a derivative of nitrofuran. It has a bactericidal and bacteriostatic effect in urinary tract infections, has a wide spectrum of action. Active against most strains of Escherichia coli, Staphylococcus spp., Streptococcus spp., Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Shigella sonnei, Proteus, Enterobacter spp.


Infectious and inflammatory diseases of the urinary tract, caused by microorganisms sensitive to the drug:
pyelitis; pyelonephritis; cystitis; urethritis;
Prevention of infections during urological operations or examination (cystoscopy, catheterization, etc.).


active substance: 100 mg nitrofurantoin

Nitrofurantoin is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Furadonin Olainfarm Latvia pills
Furadonin Irbit HFZ Russia pills
Furadonin BPMP Belarus pills

No customer reviews for the moment.

Write your review

Write your review

Furadonin® [Nitrofurantoin]

Dosage and Administration

Inside, drinking plenty of water, adults - 0.1-0.15 g, 3-4 times a day; children - at the rate of 5-8 mg / kg / day, the daily dose is divided into 4 doses. Higher doses for adults: single - 0.3 g, daily - 0.6 g.

For acute urinary tract infections, the duration of treatment is 7-10 days.

Preventive, anti-relapse treatment continues, depending on the nature of the disease, from 3 to 12 months. The daily dose in this case is 1-2 mg / kg.

Adverse reactions

Nausea, vomiting, allergic reactions (lupus-like syndrome, arthralgia, myalgia, anaphylaxis, chills, eosinophilia, rash), dizziness, headache, asthenia, nystagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, nonstagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, nonstagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, nonstagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, dysfunction, dysphagia, dysfunction , hepatitis, cholestatic syndrome, peripheral neuropathy, pancreatitis, pseudomembranous enterocolitis, rarely - abdominal pain, diarrhea.


  • Hypersensitivity, chronic renal failure;
  • heart failure II – III century;
  • cirrhosis of the liver;
  • chronic hepatitis;
  • deficiency of glucose-6-phosphate dehydrogenase;
  • acute porphyria;
  • pregnancy and lactation;
  • children's age up to 3 years.

Drug interactions

The simultaneous use of nalidixic acid and antacids containing magnesium trisilikat reduces the antibacterial effect.

Incompatibility with fluoroquinolones.

Drugs that block tubular secretion, reduce the antibacterial effect (by reducing the concentration of nitrofurantoin in the urine) and increase the toxicity (increased concentration in the blood) of the drug.

Pregnancy and Lactation

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Special instructions

Impact on the ability to drive vehicles and other mechanisms that require high concentration of attention

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor speed (with the appearance of dizziness and drowsiness).


Symptoms: vomiting.

Treatment: the intake of large amounts of fluid leads to an increase in the excretion of the drug in the urine. Effective dialysis.

Studies and clinical trials of Nitrofurantoin (Click to expand)
  1. Quantitative Bestimmung von Nitrofurantoin im Urin
  2. Quantitative Bestimmung von Nitrofurantoin in Körperflüssigkeiten durch HPLC mit Direktinjektion
  3. Polarographische Simultanbestimmung von Nitrofurantoin und Phenazopyridin in Tabletten
  4. Nitrofurantoin-induced antinuclear antibodies and panniculitis
  5. Absorption and disposition characteristics of nitrofurantoin in dogs
  6. Electrochemical behavior of nitrofurantoin and assay of its formulations
  7. Comparison of genomic damage caused by 5-nitrofurantoin in young and adult mice using the in vivo micronucleus assay
  8. Adaptive response of vibrio cholerae and escherichia coli to nitrofurantoin
  9. Comparison of the genetic activity of AF-2 and nitrofurantoin in log and stationary phase cells of saccharomyces cerevisiae
  10. Inhibition studies on the involvement of flavoprotein reductases in menadione- and nitrofurantoin-stimulated oxyradical production by hepatic microsomes of flounder (Platichthys flesus)
  11. Effect of pregnancy on nitrofurantoin disposition in mice
  12. Integrated approach to study the dehydration kinetics of nitrofurantoin monohydrate
  13. Nitrofurantoin–p-aminobenzoic acid cocrystal: Hydration stability and dissolution rate studies
  14. Laboratory studies with nitrofurantoin. Relationship between crystal size, urinary excretion in the rat and man, and emesis in dogs
  15. Urinary drug excretion in dogs during therapeutic doses of different nitrofurantoin dosage forms
  16. Detection of ampicillin contamination in nitrofurantoin preparations by high pressure liquid chromatography
  17. Inconsistencies in rationale underlying official USP dissolution rate specifications for nitrofurantoin
  18. pH-dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules
  19. Bioavailability of 14 nitrofurantoin products
  20. Nitrofurantoin solubility in aqueous urea solutions
  21. Effect of propantheline on nitrofurantoin absorption
  22. Determination of nitrofurantoin in urine by reduction at rotating platinum electrode

Customers who bought this product also bought:

8 other products in the same category: